Gold ticks up but remains pressured by Fed rate caution, easing trade fears
DUBLIN - Bank of America Corporation has disclosed a 2.98% stake in Avadel Pharmaceuticals plc, according to a regulatory filing released Today.
The disclosure, made under the Irish Takeover Panel rules, shows Bank of America holds interests in 2,903,978 shares, representing 2.981% of the company. The position includes 2,478,603 owned and controlled relevant securities and 425,375 shares through cash-settled derivatives.
The filing also reveals Bank of America has short positions in 1,906,192 shares, equivalent to 1.957% of Avadel Pharmaceuticals. These short positions consist of 674,210 relevant securities and 1,231,982 cash-settled derivatives.
The disclosure documents multiple transactions conducted on October 29, 2025, including purchases of Avadel shares at prices ranging from $18.59 to $18.93 per share, and sales at prices between $18.59 and $18.94.
Bank of America also reported several cash-settled derivative transactions, primarily involving the reduction of short positions.
The filing was made in accordance with Rule 8.3 of the Irish Takeover Panel Act, which requires disclosure of interests representing 1% or more in companies involved in takeover situations.
Avadel Pharmaceuticals, listed on the Nasdaq, is a specialty pharmaceutical company. The disclosure was made through a regulatory news service as required by the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.